Compare IMNM & CHRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | CHRN |
|---|---|---|
| Founded | 2006 | 2026 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2020 | 2012 |
| Metric | IMNM | CHRN |
|---|---|---|
| Price | $17.97 | $14.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 2 |
| Target Price | ★ $35.19 | $28.50 |
| AVG Volume (30 Days) | ★ 1.4M | 122.7K |
| Earning Date | 11-05-2026 | 10-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.40 | ★ 92.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,941,000.00 | N/A |
| Revenue This Year | N/A | $84.77 |
| Revenue Next Year | $18,803.97 | $603.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.64 | $12.62 |
| 52 Week High | $30.06 | $30.00 |
| Indicator | IMNM | CHRN |
|---|---|---|
| Relative Strength Index (RSI) | 35.71 | 36.17 |
| Support Level | $17.83 | $12.62 |
| Resistance Level | $23.48 | $22.29 |
| Average True Range (ATR) | 0.98 | 1.51 |
| MACD | 0.14 | -0.19 |
| Stochastic Oscillator | 32.67 | 27.49 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
ChronoScale Holdings Corp is providing cloud services to customers at third-party colocation centers located in Colorado, Minnesota and Utah, such as artificial intelligence and machine learning developers, seeking to develop their products. It design, develop, and market exoskeleton and complementary products that augment human strength, endurance, and mobility. Its Cloud Business provides graphics processing unit (GPU) computing solutions that enable customers to execute critical workloads related to artificial intelligence (AI), machine learning (ML), rendering, and other High Performance Computing (HPC) tasks at scale in a capacity-constrained market. It has one operating segment Cloud Business.